Drugs / Psidium guajava extract
Psidium guajava extract
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04810728 | Jun → Dec 2020 | COVID-19 | Baiturrahmah University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Psidium guajava extract | “The study aimed to determine the effects of Psidium guajava extract supplementation on inflammation markers of asymptomatic and mild COVID-19 patients.” PMID 37009425 ↗ Mar 2023 |
| Known as | Extract Psidii guava | “2 Capsule of extract Psidii guava, three times daily” NCT04810728 ↗ |
| Known as | guava leaf extract | “One of the herbs standardized that was commonly used in Indonesia is extracted Psidii guava, which is known as a guava leaf extract.” NCT04810728 ↗ |
| Known as | P. guajava extract | “This study was an experimental, single-blinded, randomized clinical trial (ClinicalTrials.gov: NCT04810728) comparing the efficacy of P. guajava extract at the dose of...” PMID 37009425 ↗ Mar 2023 |